How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
BURLINGTON, Mass., March 02, 2017 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to provide an update on business operations and report its fiscal year 2016 financial results on Thursday, March 9, 2017, at 4:30 p.m. ET.
The dial-in number for the conference call is (855) 770-0022 for domestic participants and (908) 982-4677 for international participants, with Conference ID # 77592180. A live webcast of the conference call can also be accessed through the “Investors” tab on the Flexion Therapeutics website. A webcast replay will be available online after the call.
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with OA of the knee. The company's lead product candidate, Zilretta, is being investigated for its potential to provide improved analgesia for the millions of U.S. patients who receive intra-articular injections for OA related knee pain annually.
Corporate Contacts: Fred Driscoll Chief Financial Officer Flexion Therapeutics, Inc. T: 781-305-7763 [email protected] Scott Young Sr. Director, Corporate Communications & Investor Relations Flexion Therapeutics, Inc. T: 781-305-7194 [email protected] Investor Contact: David Carey Lazar Partners LTD T: 212-867-1768 [email protected]
